Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caroline Cohen

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Pharmacology, Biochemistry, and Behavior|December 1, 2010
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognitionNancy Rogacki, Matilde Lopez-Grancha, Vanessa Naimoli, et al.
CNS Drug Reviews|February 22, 2003
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasmsGuy Griebel, Ghislaine Perrault, Jacques Simiand, et al.
Annals of Emergency Medicine|June 18, 2026
Improving End-of-Life Screening in the Emergency Department With Collaborative Artificial IntelligenceAdrian D Haimovich, Gabriel Erion-Barner, Larry A Nathanson, et al.
NPJ Parkinson'S Disease|March 14, 2024
Disease progression strikingly differs in research and real-world Parkinson's populationsBrett K Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, et al.
Medrxiv : the Preprint Server for Health Sciences|February 26, 2024
Disease progression strikingly differs in research and real-world Parkinson's populationsBrett K Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 27, 2007
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disordersJeanne Stemmelin, Caroline Cohen, Jean-Paul Terranova, et al.
Psychopharmacology|December 25, 2010
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodentsMark D Black, Rachel J Stevens, Nancy Rogacki, et al.
BMC Neurology|May 19, 2021
Accelerating diagnosis of Parkinson's disease through risk predictionWilliam Yuan, Brett Beaulieu-Jones, Richard Krolewski, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2008
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay, Philippe Pichat, Gihad Dargazanli, et al.
Alzheimer'S Research & Therapy|November 30, 2018
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Pharmacology, Biochemistry, and Behavior|December 1, 2010
The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognitionNancy Rogacki, Matilde Lopez-Grancha, Vanessa Naimoli, et al.
CNS Drug Reviews|February 22, 2003
SL651498, a GABAA receptor agonist with subtype-selective efficacy, as a potential treatment for generalized anxiety disorder and muscle spasmsGuy Griebel, Ghislaine Perrault, Jacques Simiand, et al.
Annals of Emergency Medicine|June 18, 2026
Improving End-of-Life Screening in the Emergency Department With Collaborative Artificial IntelligenceAdrian D Haimovich, Gabriel Erion-Barner, Larry A Nathanson, et al.
NPJ Parkinson'S Disease|March 14, 2024
Disease progression strikingly differs in research and real-world Parkinson's populationsBrett K Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, et al.
Medrxiv : the Preprint Server for Health Sciences|February 26, 2024
Disease progression strikingly differs in research and real-world Parkinson's populationsBrett K Beaulieu-Jones, Francesca Frau, Sylvie Bozzi, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|April 27, 2007
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disordersJeanne Stemmelin, Caroline Cohen, Jean-Paul Terranova, et al.
Psychopharmacology|December 25, 2010
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodentsMark D Black, Rachel J Stevens, Nancy Rogacki, et al.
BMC Neurology|May 19, 2021
Accelerating diagnosis of Parkinson's disease through risk predictionWilliam Yuan, Brett Beaulieu-Jones, Richard Krolewski, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2008
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay, Philippe Pichat, Gihad Dargazanli, et al.
Alzheimer'S Research & Therapy|November 30, 2018
SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)Laurent Pradier, Véronique Blanchard-Brégeon, Andrees Bohme, et al.
Pageof 4